

HCV/HIV Co-Infection and PUBLIC POLICY

M. Monica Sweeney, MD, MPH, FACP

Vice Dean for Global Engagement

Clinical Professor

Chair-Department of Health Policy & Management

School of Public Health

State University of New York Downstate Medical Center

Brooklyn, New York

November 15, 2015

Objectives

- Participants will be able to
 - Negotiate the “system” to access antiviral drugs for patients with HVC
 - Describe to patients the challenge of treating co-infection with HCV/HIV

Prevalence

- HIV
- HCV greatly underestimated
- HCV/HIV Co-infection very different based on the population discussed

What the Co-Infected Patient Needs to Know

- Treatment and follow-up will be a life-long partnership between the patient and team of caregivers
- Unless one is very rich, or has the best insurance coverage* there are likely to be financial challenges
- There is stigma related to both diseases, sharing one's status with close family members improves health outcomes
- Each person with co-infection has different needs as far as their treatment**

Negotiating the “System #1”

➤ Medicare Part D

- Dual Eligible Care/Caid

➤ Medicaid***

- Private Insurance (often with a co-pay that puts it out of the reach of many patients)

Negotiating the “System #2”

- Finding a FQHC which has to either treat you or have an MOU with a treating healthcare facility
 - The cost is free or a sliding fee schedule based on income. Regardless of documentation status

- Pharma Patient Assistance Programs.
 - ***The Crown Jewel***
 - The Partnership for Prescription Assistance
www.liverfoundation.org

About us

P/RMA

Our mission is to increase awareness of patient assistance programs and boost enrollment of those who are eligible. We offer a single point of access to more than 475 public and private programs, including nearly 200 offered by biopharmaceutical companies. We have already helped millions of Americans get free or reduced-cost prescription medicines. [Read more >](#)



NEARLY 9.5 MILLION AMERICANS HAVE RECEIVED ASSISTANCE



ESTABLISHED IN 2005

See All Partners

abbvie

 astellas

AstraZeneca 

 Bayer

Boehringer
Ingelheim
Cares
Foundation
...more health

 Celgene

ENCourage Foundation®

Johnson & Johnson
PATIENT ASSISTANCE
FOUNDATION, INC.

Lilly

 Mallinckrodt
Pharmaceuticals

 MERCK
Be well

 NOVARTIS

 Pfizer

SANOFI 

 Takeda

The
Safety Net Foundation

Individual Pharma Patient Assistance Programs

Gilead

<https://harvoni.com>

Harvoni Support Path 1-855-769-7284.

Co-pay coupons

Financial support 24/7 live nurse support

Bristol Meyers Squibb

Has a foundation for patient assistance but at this point,
has several medications for treatment of HVC in the pipeline

Health Departments

CALIFORNIA'S HEALTH AND SAFETY CODE SECTION 122400-122435

Is the model for any State that hasn't developed a comprehensive pilot for;

Education

Screening, Treatment

Financing

For all California residents.

Federal Regulations stipulates that Medicaid Agencies must cover FDA approved drugs marketed by companies that have negotiated rebates with the Federal Medicaid drug-rebate program. Federal law allows states the discretion of implementing prior-authorization criteria as they see fit.

Thank you!!